{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:06:41Z","timestamp":1790831201413,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1A2C301016611"],"award-info":[{"award-number":["2021R1A2C301016611"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1I1A1A01071162"],"award-info":[{"award-number":["2022R1I1A1A01071162"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1F1A1063854"],"award-info":[{"award-number":["2021R1F1A1063854"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021M2E8A1049151"],"award-info":[{"award-number":["2021M2E8A1049151"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.canlet.2023.216456","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T23:03:18Z","timestamp":1699311798000},"page":"216456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Oncolytic adenovirus as pancreatic cancer-targeted therapy: Where do we go from here?"],"prefix":"10.1016","volume":"579","author":[{"given":"A-Rum","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinWoo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Kyeong","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Min","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songnam","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae-Ok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2023.216456_bib1","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1007\/s00018-019-03444-3","article-title":"Hypoxia: a barricade to conquer the pancreatic cancer","volume":"77","author":"Tan","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.canlet.2023.216456_bib2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fphys.2014.00141","article-title":"Role of pancreatic stellate cells in chemoresistance in pancreatic cancer","volume":"5","author":"McCarroll","year":"2014","journal-title":"Front. Physiol."},{"key":"10.1016\/j.canlet.2023.216456_bib3","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.2147\/IJN.S413496","article-title":"Advances and prospects in the treatment of pancreatic cancer","volume":"18","author":"Duan","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2023.216456_bib4","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.1038\/s41598-020-64068-3","article-title":"Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study","volume":"10","author":"Wang","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2023.216456_bib5","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/1744666X.2022.2120471","article-title":"Combination immunotherapy for pancreatic cancer: challenges and future considerations","volume":"18","author":"G\u00f6ssling","year":"2022","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.canlet.2023.216456_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820948773","article-title":"Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers","volume":"13","author":"Eso","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.canlet.2023.216456_bib7","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216456_bib8","doi-asserted-by":"crossref","first-page":"8117","DOI":"10.1007\/s00432-023-04735-w","article-title":"Oncolytic adenoviruses and the treatment of pancreatic cancer: a review of clinical trials","volume":"149","author":"Taylor","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2023.216456_bib9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2023.216456_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228627","article-title":"Oncolytic viruses and immune checkpoint inhibitors: preclinical developments to clinical trials","volume":"21","author":"Hwang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2023.216456_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953410","article-title":"Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements","volume":"13","author":"Yun","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2023.216456_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.copbio.2019.11.016","article-title":"Design and application of oncolytic viruses for cancer immunotherapy","volume":"65","author":"Yl\u00f6sm\u00e4ki","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.canlet.2023.216456_bib13","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/14712598.2020.1757066","article-title":"Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity","volume":"20","author":"Pelin","year":"2020","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.canlet.2023.216456_bib14","article-title":"Oncolytic adenovirus: prospects for cancer immunotherapy","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.canlet.2023.216456_bib15","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1172\/JCI9973","article-title":"Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer","volume":"105","author":"Hermiston","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2023.216456_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/(SICI)1521-2254(200003\/04)2:2<141::AID-JGM93>3.0.CO;2-2","article-title":"Cancer gene therapy--new approaches to tumour cell killing","volume":"2","author":"Vile","year":"2000","journal-title":"J. Gene Med."},{"key":"10.1016\/j.canlet.2023.216456_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0042-6822(61)90051-4","article-title":"Biochemical studies on adenovirus multiplication. II. Kinetics of nucleic acid and protein synthesis in suspension cultures","volume":"13","author":"Green","year":"1961","journal-title":"Virology"},{"key":"10.1016\/j.canlet.2023.216456_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.875188","article-title":"An extensive review on preclinical and clinical trials of oncolytic viruses therapy for pancreatic cancer","volume":"12","author":"Nisar","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2023.216456_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.875188","article-title":"An extensive review on preclinical and clinical trials of oncolytic viruses therapy for pancreatic cancer","volume":"12","author":"Nisar","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2023.216456_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.omto.2018.01.002","article-title":"Adenovirus-mediated delivery of decoy hyper binding sites targeting oncogenic HMGA1 reduces pancreatic and liver cancer cell viability","volume":"8","author":"Hassan","year":"2018","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.canlet.2023.216456_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.230","article-title":"RGD-modified oncolytic adenovirus-harboring shPKM2 exhibits a potent cytotoxic effect in pancreatic cancer via autophagy inhibition and apoptosis promotion","volume":"8","author":"Xu","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2023.216456_bib22","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/ijc.31060","article-title":"Potent antitumor effect of tumor microenvironment-targeted oncolytic adenovirus against desmoplastic pancreatic cancer","volume":"142","author":"Li","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2023.216456_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canlet.2019.05.033","article-title":"Oncolytic Ad co-expressing decorin and Wnt decoy receptor overcomes chemoresistance of desmoplastic tumor through degradation of ECM and inhibition of EMT","volume":"459","author":"Li","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216456_bib24","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nature04478","article-title":"Angiogenesis in life, disease and medicine","volume":"438","author":"Carmeliet","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2023.216456_bib25","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/S0140-6736(08)60770-9","article-title":"Targeting angiogenesis in pancreatic cancer","volume":"371","author":"Philip","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2023.216456_bib26","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1089\/104303402760372954","article-title":"Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein","volume":"13","author":"Sauthoff","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.canlet.2023.216456_bib27","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0360-3016(02)03005-5","article-title":"Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model","volume":"54","author":"Freytag","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2023.216456_bib28","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1128\/JVI.73.6.4983-4990.1999","article-title":"Adenovirus-mediated p21((WAF1\/SDII\/CIP1)) gene transfer induces apoptosis of human cervical cancer cell lines","volume":"73","author":"Tsao","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.canlet.2023.216456_bib29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the light: the growing complexity of p53","volume":"137","author":"Vousden","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2023.216456_bib30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.14701\/ahbps.2021.25.3.315","article-title":"Mutations of p53 associated with pancreatic cancer and therapeutic implications","volume":"25","author":"Voutsadakis","year":"2021","journal-title":"Ann. Hepatobiliary. Pancreat. Surg."},{"key":"10.1016\/j.canlet.2023.216456_bib31","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ejca.2011.12.020","article-title":"A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression","volume":"48","author":"Yamasaki","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2023.216456_bib32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.omto.2020.03.016","article-title":"Oncolytic virus-mediated targeting of the ERK signaling pathway inhibits invasive propensity in human pancreatic cancer","volume":"17","author":"Koujima","year":"2020","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.canlet.2023.216456_bib33","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00262-022-03334-x","article-title":"Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer","volume":"72","author":"Kajiwara","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2023.216456_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.omto.2022.09.003","article-title":"Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer","volume":"27","author":"Araki","year":"2022","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.canlet.2023.216456_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0625.2007.00655.x","article-title":"Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma","volume":"17","author":"Eberle","year":"2008","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.canlet.2023.216456_bib36","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.cgt.7700969","article-title":"The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer","volume":"13","author":"Zhao","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2023.216456_bib37","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1089\/hum.2020.024","article-title":"Oncolytic adenovirus expressing ST13 increases antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic ductal adenocarcinoma","volume":"31","author":"Zhang","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.canlet.2023.216456_bib38","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.3892\/mmr.2017.6472","article-title":"Synergistic antitumor effects of CDK inhibitor SNS-032 and an oncolytic adenovirus co-expressing TRAIL and Smac in pancreatic cancer","volume":"15","author":"Ge","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.canlet.2023.216456_bib39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10495-015-1208-z","article-title":"Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells","volume":"21","author":"Han","year":"2016","journal-title":"Apoptosis"},{"key":"10.1016\/j.canlet.2023.216456_bib40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1756-8722-6-18","article-title":"SNS-032 inhibits mTORC1\/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt","volume":"6","author":"Meng","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2023.216456_bib41","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-11-1971","article-title":"Cyclin-dependent kinase 7\/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor \u03b1 and bcr-abl oncogene addiction in malignant hematologic cells","volume":"18","author":"Wu","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216456_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114893","article-title":"Suicide gene therapy in cancer and HIV-1 infection: an alternative to conventional treatments","volume":"197","author":"Saeb","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2023.216456_bib43","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.gie.2020.02.012","article-title":"Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial","volume":"92","author":"Lee","year":"2020","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.canlet.2023.216456_bib44","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/PPO.0000000000000140","article-title":"Orchestrating the tumor microenvironment to improve survival for patients with pancreatic cancer: normalization, not destruction","volume":"21","author":"Whatcott","year":"2015","journal-title":"Cancer J."},{"key":"10.1016\/j.canlet.2023.216456_bib45","first-page":"356","article-title":"Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy","volume":"10","author":"Yun","year":"2008","journal-title":"Curr. Opin. Mol. Therapeut."},{"key":"10.1016\/j.canlet.2023.216456_bib46","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/nrc1750","article-title":"Recent progress in the battle between oncolytic viruses and tumours","volume":"5","author":"Parato","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2023.216456_bib47","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jnci\/djj397","article-title":"Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy","volume":"98","author":"Kim","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2023.216456_bib48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2017.03.009","article-title":"Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer","volume":"396","author":"Jung","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216456_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000763","article-title":"Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade","volume":"8","author":"Jung","year":"2020","journal-title":"J. Immunother Cancer"},{"key":"10.1016\/j.canlet.2023.216456_bib50","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/gt.2009.142","article-title":"Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy","volume":"17","author":"Choi","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2023.216456_bib51","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0002-9440(10)64757-8","article-title":"Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival","volume":"156","author":"Auvinen","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2023.216456_bib52","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0959-8049(00)00448-2","article-title":"High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer","volume":"37","author":"Lipponen","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2023.216456_bib53","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/1078-0432.CCR-20-2400","article-title":"Modification of extracellular matrix enhances oncolytic adenovirus immunotherapy in glioblastoma","volume":"27","author":"Kiyokawa","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216456_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat9321","article-title":"Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01","volume":"11","author":"Pascual-Pasto","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2023.216456_bib55","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/1078-0432.CCR-14-2213","article-title":"Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression","volume":"21","author":"Rodr\u00edguez-Garc\u00eda","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216456_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003254","article-title":"VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects","volume":"9","author":"Bazan-Peregrino","year":"2021","journal-title":"J. Immunother Cancer"},{"key":"10.1016\/j.canlet.2023.216456_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003255","article-title":"Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors","volume":"10","author":"Garcia-Carbonero","year":"2022","journal-title":"J. Immunother Cancer"},{"key":"10.1016\/j.canlet.2023.216456_bib58","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.vascn.2008.07.003","article-title":"Influence of method of systemic administration of adenovirus on virus-mediated toxicity: focus on mortality, virus distribution, and drug metabolism","volume":"58","author":"Boquet","year":"2008","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.canlet.2023.216456_bib59","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","article-title":"Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection","volume":"5","author":"Garcia-Carbonero","year":"2017","journal-title":"J. Immunother Cancer"},{"key":"10.1016\/j.canlet.2023.216456_bib60","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.gt.3302347","article-title":"Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice","volume":"12","author":"Varnavski","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2023.216456_bib61","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12943-023-01813-y","article-title":"Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma","volume":"22","author":"Gautam","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2023.216456_bib62","article-title":"Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: current research and future perspective","volume":"13","author":"Li","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2023.216456_bib63","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13046-022-02273-w","article-title":"Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy","volume":"41","author":"Liu","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216456_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.688377","article-title":"The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy","volume":"11","author":"Principe","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2023.216456_bib65","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/gt.2011.125","article-title":"Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF","volume":"19","author":"Choi","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2023.216456_bib66","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1007\/s11033-013-2638-8","article-title":"Cancer targeting gene-viro-therapy for pancreatic cancer using oncolytic adenovirus ZD55-IL-24 in immune-competent mice","volume":"40","author":"He","year":"2013","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.canlet.2023.216456_bib67","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination","volume":"77","author":"Jiang","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216456_bib68","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.surg.2015.01.006","article-title":"Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer","volume":"157","author":"LaRocca","year":"2015","journal-title":"Surgery"},{"key":"10.1016\/j.canlet.2023.216456_bib69","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1006\/cimm.1994.1192","article-title":"Cooperation of natural killer cell stimulatory factor\/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells","volume":"156","author":"Aste-Amezaga","year":"1994","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.canlet.2023.216456_bib70","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2023.216456_bib71","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1084\/jem.181.3.901","article-title":"Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids","volume":"181","author":"Orange","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2023.216456_bib72","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M","article-title":"Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer","volume":"83","author":"Kammula","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2023.216456_bib73","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1749-6632.1996.tb52715.x","article-title":"Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials","volume":"795","author":"Lotze","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.canlet.2023.216456_bib74","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jconrel.2017.03.028","article-title":"Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy","volume":"259","author":"Oh","year":"2017","journal-title":"J. Contr. Release"},{"issue":"No 3","key":"10.1016\/j.canlet.2023.216456_bib75","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.13972","article-title":"Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model","volume":"8","author":"Oh","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2023.216456_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106701","article-title":"Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma","volume":"189","author":"Fang","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.canlet.2023.216456_bib77","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s44222-023-00030-y","article-title":"Engineering cytokine therapeutics","volume":"1","author":"Deckers","year":"2023","journal-title":"Nature Reviews Bioengineering"},{"key":"10.1016\/j.canlet.2023.216456_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202100035","article-title":"Engineering strategies for immunomodulatory cytokine therapies: challenges and clinical progress","volume":"4","author":"Pires","year":"2021","journal-title":"Adv. Therapeutics"},{"key":"10.1016\/j.canlet.2023.216456_bib79","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-017-01385-8","article-title":"Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent","volume":"8","author":"Wang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2023.216456_bib80","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s42003-021-01914-8","article-title":"Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors","volume":"4","author":"Rosewell Shaw","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.canlet.2023.216456_bib81","article-title":"Ultralow-dose binary oncolytic\/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies","volume":"9","author":"Wang","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2023.216456_bib82","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb6596","article-title":"Relaxin gene delivery modulates macrophages to resolve cancer fibrosis and synergizes with immune checkpoint blockade therapy","volume":"7","author":"Zhou","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2023.216456_bib83","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2023.216456_bib84","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J. Immunother Cancer"},{"key":"10.1016\/j.canlet.2023.216456_bib85","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.23552","article-title":"High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006","volume":"113","author":"Klapper","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2023.216456_bib86","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10975","article-title":"Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'","volume":"484","author":"Levin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2023.216456_bib87","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/2159-8290.CD-18-1495","article-title":"A first-in-human study and biomarker analysis of NKTR-214, a novel IL2R\u03b2\u03b3-biased cytokine, in patients with advanced or metastatic solid tumors","volume":"9","author":"Bentebibel","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2023.216456_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.674400","article-title":"Oncolytic adenovirus coding for a variant interleukin 2 (vIL-2) cytokine Re-programs the tumor microenvironment and confers enhanced tumor control","volume":"12","author":"Quixabeira","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2023.216456_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1171083","article-title":"An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage","volume":"14","author":"Pakola","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2023.216456_bib90","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2023.216456_bib91","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","article-title":"Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer","volume":"27","author":"Byrne","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216456_bib92","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005471","article-title":"First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors","volume":"10","author":"Hamid","year":"2022","journal-title":"J. Immunother Cancer"},{"key":"10.1016\/j.canlet.2023.216456_bib93","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1158\/1078-0432.CCR-22-2103","article-title":"Combination nivolumab, CD137 agonism, and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"28","author":"Hall","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216456_bib94","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1158\/1078-0432.CCR-17-0285","article-title":"Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus","volume":"23","author":"Eriksson","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216456_bib95","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4138","article-title":"A phase I\/II study of LOAd703, a TMZ-CD40L\/4-1BBL-armed oncolytic adenovirus, combined with nab-paclitaxel and gemcitabine in advanced pancreatic cancer","volume":"40","author":"Musher","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2023.216456_bib96","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1158\/1078-0432.CCR-19-1395","article-title":"A virus-infected, reprogrammed somatic cell-derived tumor cell (VIReST) vaccination regime can prevent initiation and progression of pancreatic cancer","volume":"26","author":"Lu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216456_bib97","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1038\/s41467-021-22929-z","article-title":"Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination","volume":"12","author":"Roy","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2023.216456_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2023.101334","article-title":"Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19","volume":"61","author":"Afkhami","year":"2023","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.canlet.2023.216456_bib99","article-title":"Effectiveness and safety of COVID-19 vaccinations: an umbrella meta-analysis","volume":"68","author":"Jiesisibieke","year":"2023","journal-title":"Internet J. Publ. Health"},{"key":"10.1016\/j.canlet.2023.216456_bib100","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1080\/14760584.2023.2242528","article-title":"A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov","volume":"22","author":"Wang","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.canlet.2023.216456_bib101","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00705-022-05432-8","article-title":"Viruses as tools in gene therapy, vaccine development, and cancer treatment","volume":"167","author":"Bin Umair","year":"2022","journal-title":"Arch. Virol."},{"key":"10.1016\/j.canlet.2023.216456_bib102","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005702","article-title":"First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)","volume":"11","author":"Autio","year":"2023","journal-title":"J. Immunother Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352300407X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352300407X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:05:33Z","timestamp":1777550733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352300407X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":102,"alternative-id":["S030438352300407X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216456","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic adenovirus as pancreatic cancer-targeted therapy: Where do we go from here?","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216456"}}